Acurx Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Acurx Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($7.97M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($14.10M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($14.58M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($12.09M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.75M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($4.60M) | Mar 16, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.09M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($14.12M) | Mar 12, 2026 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.83M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.40M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $6.04M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $4.75M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $2.03M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.20M | Mar 16, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $208.3K | Mar 16, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.79M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($10.38M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($9.80M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($7.54M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($5.01M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($3.35M) | Mar 16, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.69M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.71M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $9.38M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $13.25M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $3.22M | Mar 16, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.42M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.24M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.04M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $2.06M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | $843.9K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $522.4K | Mar 16, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.27M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $615.1K | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.67M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $7.32M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $12.41M | Mar 15, 2024 |
| FY2022 | Dec 31, 2020 | $2.70M | Mar 15, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.29M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($67.32M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($53.22M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($38.64M) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | ($26.55M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($13.80M) | Mar 16, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (17) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.35M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 851,534 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 14.47M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 11.63M | Mar 15, 2024 |
| FY2022 | Dec 31, 2021 | 10.22M | Mar 15, 2023 |